PET imaging of oestrogen receptors in patients with breast cancer

The Lancet Oncology

Volumn 14, Issue 11, 2013, Pages

  van Kruchten, Michel ^a   de Vries, Elisabeth G E ^a   Brown, Myles ^b   de Vries, Erik F J ^a   Glaudemans, Andor W J M ^a   Dierckx, Rudi A J O ^a   Schröder, Carolien P ^a   Hospers, Geke A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA FLUOROESTRADIOL F 18; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; HORMONE; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; UNCLASSIFIED DRUG;

BODY COMPOSITION; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL SPECIFICITY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG TUMOR LEVEL; HUMAN; LIVER FUNCTION; LIVER METABOLISM; LIVER METASTASIS; LOADING DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MENOPAUSE; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; WHOLE BODY PET;

EID: 84884698432     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70292-4     Document Type: Review

References (86)

1. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30:587-592.
2. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007, 87:662-669.
3. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988, 169:45-48.
4. Mosselman S, Polman J, Dijkema R ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49-53.
5. Ahmad N, Kumar R Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett 2011, 300:1-9.
6. Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008, 26:3727-3734.
7. Younes M, Honma N Estrogen receptor β. Arch Pathol Lab Med 2011, 135:63-66.
8. Allred DC, Harvey JM, Berardo M, Clark GM Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
9. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
10. Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981, 47:554-560.
11. Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol 2012, 23(suppl 10):x349-x353.
12. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504.
13. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30:2601-2608.
14. Jones T, Price P Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncol 2012, 13:e116-e125.
15. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37:181-200.
16. 18F]fluoro-17β-estradiol. J Med Chem 2005, 48:6366-6378.
17. VanBrocklin HF, Liu A, Welch MJ, O'Neil JP, Katzenellenbogen JA The synthesis of 7α-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents. Steroids 1994, 59:34-45.
18. Pomper MG, VanBrocklin H, Thieme AM, et al. 11β-methoxy-, 11β-ethyl- and 17α-ethynyl-substituted 16α-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem 1990, 33:3143-3155.
19. 18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice. Eur J Nucl Med Mol Imaging 2008, 35:1473-1479.
20. 18F]fluoroestradiols: selective receptor-based PET imaging agents. Int J Rad Appl Instrum B 1992, 19:363-374.
21. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984, 25:1212-1221.
22. 18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice. Nucl Med Biol 2012, 39:57-64.
23. 18F]fluoro)-17β-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum B 1987, 14:15-25.
24. 18F]-fluoro-17β-estradiol in rat. Ann Nucl Med 2000, 14:127-130.
25. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002, 67:765-775.
26. Mendel CM The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 1989, 10:232-274.
27. Fortunati N, Becchis M, Catalano MG, et al. Sex hormone-binding globulin, its membrane receptor, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells. J Steroid Biochem Mol Biol 1999, 69:473-479.
28. 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 2011, 38:969-978.
29. 18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 1999, 26:123-130.
30. 18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. J Med Chem 1993, 36:1619-1629.
31. Neto C, Oliveira MC, Gano L, et al. Novel 7α-alkoxy-17α-(4'-halophenylethynyl)estradiols as potential SPECT/PET imaging agents for estrogen receptor expressing tumours: synthesis and binding affinity evaluation. Steroids 2012, 77:1123-1132.
32. Lee JH, Peters O, Lehmann L, et al. Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target. Nucl Med Biol 2012, 39:1105-1116.
33. 99mTc-TOR-DTPA). Cancer Biother Radiopharm 2009, 34:707-716.
34. Van de Wiele C, Cocquyt V, VandenBroecke R, et al. Iodine-labeled tamoxifen uptake in primary human breast Ccarcinoma. J Nucl Med 2001, 42:1818-1820.
35. Bennink RJ, van Tienhoven G, Rijks LJ, Noorduyn AL, Janssen AG, Sloof GW In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 2004, 45:1-7.
36. Pais A, Gunanathan C, Margalit R, et al. In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. Cancer Res 2011, 71:7387-7397.
37. 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 2013, 54:499-506.
38. van Kruchten M, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med 2012, 53:182-190.
39. 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 2011, 38:969-978.
40. 18F]fluorodeoxyglucose PET. Eur J Nucl Med Mol Imaging 2011, 38:1824-1831.
41. 18F-fluoroestradiol PET. J Nucl Med 2011, 52:1541-1549.
42. Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011, 17:4799-4805.
43. 18F]fluoro-17β-oestradiol PET. Eur J Nucl Med Mol Imaging 2011, 38:37-45.
44. 18F-FDG PET. J Nucl Med 2009, 50:1598-1604.
45. 18F-fluoro-17β-estradiol PET. J Ovarian Res 2009, 2:7-16.
46. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009, 113:509-517.
47. 18F-fluoroestradiol. J Nucl Med 2008, 49:367-374.
48. Tsujikawa T, Okazawa H, Yoshida Y, et al. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia. Ann Nucl Med 2008, 22:73-77.
49. 18F fluorodeoxyglucose PET-initial experience. Radiology 2008, 248:599-605.
50. Tsuchida T, Okazawa H, Mori T, et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET-influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol 2007, 34:205-210.
51. Yoshida Y, Kurokawa T, Sawamura Y, et al. The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol 2007, 104:764-766.
52. Kanne JP, Mankoff DA, Baird GS, Minoshima S, Livingston RB Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances. AJR Am J Roentgenol 2007, 188:W503-W505.
53. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006, 24:2793-2799.
54. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001, 19:2797-2803.
55. 18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001, 42:679-684.
56. 18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999, 26:905-913.
57. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999, 26:51-56.
58. Moresco RM, Scheithauer BW, Lucignani G, et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun 1997, 18:606-615.
59. Mankoff DA, Tewson TJ, Eary JF Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-fluoroestradiol (FES). Nucl Med Biol 1997, 24:341-348.
60. 18F]fluoro-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996, 2:933-939.
61. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995, 36:1766-1774.
62. 18F] fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991, 32:1526-1531.
63. Howick J, Chalmers I, Glasziou P, et al. Oxford Centre for Evidence-Based Medicine 2011 levels of evidence (accessed Dec 17, 2012). http://www.cebm.net/index.aspx?o=5653.
64. Tonkin KS, Joy AA, Basi SK, et al. The potential of using discordance of estrogen PET (FES-PET) and glucose PET (FDG-PET) scans and pathologic characteristics including HER2 and Ki67 to predict for hormone insensitivity in women with metastatic breast cancer. Cancer Res 2010, 70(suppl 2). abstract PD05-04).
65. 18F-Fluoroestradiol. Semin Nucl Med 2007, 37:470-476.
66. 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer (MBC). J Nucl Med 2012, 53(suppl 1):329.
67. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004, 10:2336-2343.
68. Johnston SR, Haynes BP, Smith IE, et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 1993, 342:1521-1522.
69. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
70. O'Brien CS, Farnie G, Howell SJ, Clarke RB Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer 2011, 2:91-103.
71. Coser KR, Wittner BS, Rosenthal NF, et al. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 2009, 106:14536-14541.
72. Gallacchi P, Schoumacher F, Eppenberger-Castori S, et al. Increased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancer. Int J Cancer 1998, 79:44-48.
73. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011, 71:1893-1903.
74. Wilson BJ, Giguere V Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 2008, 7:49-56.
75. Howell A, Sapunar F Fulvestrant revisited: efficacy and safety of the 500-mg dose. Clin Breast Cancer 2011, 11:204-210.
76. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
77. Zhao C, Koide A, Abrams J, et al. Mutation of Leu-536 in human estrogen receptor-α alters the coupling between ligand binding, transcription activation, and receptor conformation. J Biol Chem 2003, 278:27278-27286.
78. Sinkevicius KW, Burdette JE, Woloszyn K, et al. An estrogen receptor-α knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology 2008, 149:2970-2979.
79. Herynk MH, Parra I, Cui Y, et al. Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 2007, 13:3235-3243.
80. Barone I, Iacopetta D, Covington KR, et al. Phosphorylation of the mutant K303R estrogen receptor α at serine 305 affects aromatase inhibitor sensitivity. Oncogene 2010, 29:2404-2414.
81. Haynes BP, Straume AH, Geisler J, et al. Intratumoral estrogen disposition in breast cancer. Clin Cancer Res 2010, 16:1790-1801.
82. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009, 117:31-41.
83. Barkhem T, Andersson-Ross C, Hoglund M, Nilsson S Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 1997, 62:53-64.
84. Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback DG Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric 2012, 15:460-466.
85. Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996, 74:300-308.
86. Plymate SR, Stutz FH, Fariss BL Relationship between sex hormone binding globulin and estrogen receptors in breast cancer. J Clin Oncol 1984, 2:652-654.